{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:58:27Z","timestamp":1792785507218,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"the Department of Obstetrics and Gynecology"},{"name":"The First Affiliated Hospital of Xi'an Jiaotong University","id":[{"id":"https:\/\/ror.org\/02tbvhh96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.critrevonc.2020.103145","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T18:39:02Z","timestamp":1605811142000},"page":"103145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"157","author":[{"given":"Jiatao","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2020.103145_bib0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0010","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0015","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1001\/jama.291.22.2705","article-title":"Frequency of symptoms of ovarian cancer in women presenting to primary care clinics","volume":"291","author":"Goff","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0020","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/AOG.0000000000002580","article-title":"Ovarian cancer prevention and screening","volume":"131","author":"Menon","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0025","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"68","key":"10.1016\/j.critrevonc.2020.103145_bib0030","first-page":"7","article-title":"Cancer statistics","volume":"2018","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0035","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0040","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0045","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0050","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0055","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0060","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/carcin\/bgs132","article-title":"PARPs and the DNA damage response","volume":"33","author":"Sousa","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0065","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0070","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1038\/sj.onc.1206679","article-title":"Regulation and mechanisms of mammalian double-strand break repair","volume":"22","author":"Valerie","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0075","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1093\/nar\/gks270","article-title":"Homologous recombination and its regulation","volume":"40","author":"Krejci","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0080","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0085","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0090","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1158\/0008-5472.CAN-10-2352","article-title":"Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment","volume":"70","author":"Chan","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0095","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2147\/DDDT.S164553","article-title":"Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials","volume":"12","author":"Liu","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2019.06.012","article-title":"Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials","volume":"141","author":"Ruiz-Schutz","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0105","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/home."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0110","unstructured":"PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). http:\/\/www.prisma-statement.org."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0115","unstructured":"CTCAE (Common Terminology Criteria for Adverse Events). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0125","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0140","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0145","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0150","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0155","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0160","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0165","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0170","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0175","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0180","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0185","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","article-title":"Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer","volume":"14","author":"George","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0190","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1038\/ncomms12425","article-title":"Synthetic viability by BRCA2 and PARP1\/ARTD1 deficiencies","volume":"7","author":"Ding","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0200","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/gcc.22075","article-title":"Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients","volume":"52","author":"Pedersen","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0205","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0210","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/cncr.29082","article-title":"Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials","volume":"121","author":"Matulonis","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0215","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.critrevonc.2020.103145_bib0220","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1128\/MCB.24.19.8504-8518.2004","article-title":"Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells","volume":"24","author":"Bindra","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0225","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1158\/1078-0432.CCR-17-0874","article-title":"Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: multimodal functional imaging and multiplex cytokine analysis","volume":"23","author":"Ueda","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0230","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/cdd.2014.202","article-title":"PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Version 2","volume":"22","author":"Farr\u00e9s","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0240","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0245","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2018.01.010","article-title":"Management of the toxicities of common targeted therapeutics for gynecologic cancers","volume":"148","author":"Gunderson","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103145_bib0250","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2015-0268","article-title":"Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer","volume":"21","author":"Moore","year":"2016","journal-title":"Oncologist"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282030281X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282030281X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:38:23Z","timestamp":1760902703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282030281X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":50,"alternative-id":["S104084282030281X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103145","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103145"}}